Andrew Robbins, Cogent Biosciences CEO

Co­gent’s mas­to­cy­to­sis drug hits ‘home run’ in reg­is­tra­tional mid-stage tri­al

Co­gent Bio­sciences said it’s work­ing on an FDA sub­mis­sion for its sys­temic mas­to­cy­to­sis (SM) drug af­ter breez­ing through a Phase 2 tri­al in an in­do­lent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.